Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma
Release Date: February 07, 2020
Expiration Date: February 07, 2021
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Ailawadhi covers the key aspects of treatment for patients living with relapsed or refractory multiple myeloma.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with early relapsed/refractory multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Outline factors that should be considered when selecting therapy for patients with RRMM, including patient age and frailty, history of prior treatments, and early versus late relapse
- Summarize current approaches to sequencing in RRMM, focusing on the role of three-drug regimens and the future of quadruplet therapy
Factors to Consider in the Treatment of Early Relapsed/Refractory Multiple Myeloma – Sikander Ailawadhi, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 7, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sikander Ailawadhi, MD
Division of Hematology-Oncology
Dr. Sikander Ailawadhi is an Associate Professor with the Division of Hematology-Oncology at Mayo Clinic in Jacksonville, Florida. He joined the Division in 2014 when he moved from the University of Southern California, Los Angeles, where he was an academic faculty with Hematology.
Dr. Ailawadhi’s career focus has been on treatment of plasma cell disorders, namely multiple myeloma and Waldenström’s macroglobulinemia. His research has focused on understanding the epidemiology and pathophysiology of these disorders, evaluating the benefit of various therapeutic strategies in different populations based on racial-ethnic and socioeconomic diversity, as well as developing novel therapeutics by means of conducting several regional and national clinical trials. Some of these research projects have included comparison of various epidemiological and disease-related characteristics in patients with multiple myeloma, Waldenström’s macroglobulinemia and chronic lymphocytic leukemia in various ethnic subgroups of the population, exploring molecular variations in multiple myeloma patients from different age groups and ethnic backgrounds, patient knowledge, compliance and psychosocial distress analyses in hematological malignancies, investigator-initiated and cooperative group clinical trials of novel therapeutic regimens in patients with these diagnoses, and secondary analyses of large databases (eg, SEER, SEER-Medicare and NCDB) to understand practice patterns and outcomes across United States.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-001-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sikander Ailawadhi has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology. He has received grant support related to research activities from Amgen, Cellectar Biosciences, Inc., Janssen, and Pharmacyclics, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Jami Craig, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.